Review the procedural, technological, and commercial factors that have impacted the field of cancer risk evaluation for inherited cancer syndromes in the past 18 months. You’ll become familiar with the rapid expansion of commercial testing laboratories providing germline testing for hereditary cancer syndromes and the use of next-generation sequencing. Leave with an understanding of the complexities faced by clinicians when determining patient eligibility for genetic testing with third-party payers now determining eligibility and directing testing service accessibility.

**Target Audience:** Registered Nurses

**Level of Content:** Intermediate

---

**Coordinator/Speaker:**
Catherine Belt, RN, MSN, AOCN®
Senior Administrator
University of Pennsylvania Abramson Cancer Center
Philadelphia, PA
cathy.belt@uphs.upenn.edu

**Full Disclosure:**
Nothing to Disclose

**Objectives:**
At the end of this session, participants will be able to:
1. Delineate the impact of next-generation sequencing technology on the landscape of cancer risk assessment for inherited cancer syndromes and the development of targeted therapies in many types of cancers.